Data from the study showed that HEMGENIX continues to deliver sustained factor IX activity levels for up to four years post-treatment. The treatment also provides long-term bleed protection, ...

UMD researchers have discovered key mechanisms in gene regulation that could improve the design of RNA-based medicines.

BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...

New research has investigated the mechanism by which bivalency functions to poise genes for expression during cell differentiation, providing insight into a long-standing paradigm in the regulation of ...

Raymond James resumed coverage of Regenxbio (RGNX) with an Outperform rating and $27 price target The firm expects the launch of Elevidys and ...

As well as being essential in the precise packaging of DNA into the space of the nucleus, histone proteins are also the site ...

Ultragenyx Pharmaceutical RARE reported new findings from an ongoing, pivotal study of its investigational candidate, UX111 (ABO-102) AAV gene therapy, for Sanfilippo syndrome type A (MPS IIIA). Per ...

The platform enables direct, unbiased genome-wide identification and quantification of the exact position of double strand DNA breaks in edited cells.

Olive oil bioactives, including MUFAs, polyphenols, and triterpenoids, modulate gene expression linked to insulin sensitivity ...

RNA-based medicines are one of the most promising ways to fight human disease, as demonstrated by the recent successes of RNA ...

Researchers uncover key mechanisms in gene regulation that may lead to better design of RNA-based medicines.

Although gut microbiota and lipid metabolites have been suggested to be closely associated with type 2 diabetes mellitus (T2DM), the interactions between gut microbiota, ...